tiprankstipranks
Trending News
More News >
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
Advertisement

Verrica Pharmaceuticals (VRCA) Stock Statistics & Valuation Metrics

Compare
456 Followers

Total Valuation

Verrica Pharmaceuticals has a market cap or net worth of $56.39M. The enterprise value is $73.81M.
Market Cap$56.39M
Enterprise Value$73.81M

Share Statistics

Verrica Pharmaceuticals has 9,445,768 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,445,768
Owned by Insiders44.85%
Owned by Institutions0.81%

Financial Efficiency

Verrica Pharmaceuticals’s return on equity (ROE) is 7.77 and return on invested capital (ROIC) is -170.21%.
Return on Equity (ROE)7.77
Return on Assets (ROA)-1.41
Return on Invested Capital (ROIC)-170.21%
Return on Capital Employed (ROCE)-2.62
Revenue Per Employee106.56K
Profits Per Employee-1.08M
Employee Count71
Asset Turnover0.14
Inventory Turnover0.75

Valuation Ratios

The current PE Ratio of Verrica Pharmaceuticals is ―. Verrica Pharmaceuticals’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value-3.68
Price to FCF
Price to Operating Cash Flow-1.20
PEG Ratio

Income Statement

In the last 12 months, Verrica Pharmaceuticals had revenue of 7.57M and earned -76.58M in profits. Earnings per share was -14.78.
Revenue7.57M
Gross Profit5.71M
Operating Income-65.92M
Pretax Income-76.58M
Net Income-76.58M
EBITDA-65.90M
Earnings Per Share (EPS)-14.78

Cash Flow

In the last 12 months, operating cash flow was -47.34M and capital expenditures -16.00K, giving a free cash flow of -47.36M billion.
Operating Cash Flow-47.34M
Free Cash Flow-47.36M
Free Cash Flow per Share-5.01

Dividends & Yields

Verrica Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.95
52-Week Price Change-75.71%
50-Day Moving Average6.59
200-Day Moving Average6.63
Relative Strength Index (RSI)42.38
Average Volume (3m)50.72K

Important Dates

Verrica Pharmaceuticals upcoming earnings date is Nov 10, 2025, TBA (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 10, 2025
Ex-Dividend Date

Financial Position

Verrica Pharmaceuticals as a current ratio of 1.76, with Debt / Equity ratio of -81.87%
Current Ratio1.76
Quick Ratio1.68
Debt to Market Cap1.21
Net Debt to EBITDA<0.01
Interest Coverage Ratio-7.00

Taxes

In the past 12 months, Verrica Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Verrica Pharmaceuticals EV to EBITDA ratio is -0.54, with an EV/FCF ratio of -0.59.
EV to Sales4.74
EV to EBITDA-0.54
EV to Free Cash Flow-0.59
EV to Operating Cash Flow-0.59

Balance Sheet

Verrica Pharmaceuticals has $15.40M in cash and marketable securities with $38.89M in debt, giving a net cash position of $23.50M billion.
Cash & Marketable Securities$15.40M
Total Debt$38.89M
Net Cash$23.50M
Net Cash Per Share$2.49
Tangible Book Value Per Share-$1.90

Margins

Gross margin is 87.60%, with operating margin of -871.25%, and net profit margin of -1012.15%.
Gross Margin87.60%
Operating Margin-871.25%
Pretax Margin-1012.15%
Net Profit Margin-1012.15%
EBITDA Margin-870.98%
EBIT Margin-887.75%

Analyst Forecast

The average price target for Verrica Pharmaceuticals is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$20.00
Price Target Upside253.36% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast5.72%
EPS Growth Forecast55.79%

Scores

Smart Score2
AI Score46
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis